Ropes & Gray Advises Lepu Biopharma in ADC Licensing Agreement With ArriVent Biopharma for Up to $1.6 Billion
January 23, 2025
January 23, 2025
BOSTON, Massachusetts, Jan. 23 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray represented Shanghai-based Lepu Biopharma in an exclusive license agreement with ArriVent BioPharma for novel antibody-drug conjugate (ADC) MRG007, in development for gastrointestinal cancers. The transaction was announced on January 21.
Under the agreement, Lepu Biopharma has granted ArriVent exclusive rights to develop and commercialize MRG007 outside of China. Th . . .
Ropes & Gray represented Shanghai-based Lepu Biopharma in an exclusive license agreement with ArriVent BioPharma for novel antibody-drug conjugate (ADC) MRG007, in development for gastrointestinal cancers. The transaction was announced on January 21.
Under the agreement, Lepu Biopharma has granted ArriVent exclusive rights to develop and commercialize MRG007 outside of China. Th . . .